Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 42
Filtrar
Más filtros

Medicinas Complementárias
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
BMJ Case Rep ; 16(2)2023 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-36792143

RESUMEN

The clinical presentation of diabetic ketoacidosis (DKA) includes nausea, vomiting, thirst, polyuria, polydipsia, abdominal pain, tachypnoea, and change in mental status in cases of severe DKA. DKA is similar in pregnant and non-pregnant women, but in pregnant women it can be seen at lower serum glucose levels and symptoms may develop more rapidly. Most, but not all, cases occur in the second or third trimester.DKA results in reduction in uteroplacental blood flow due to osmotic diuresis, and also in metabolic abnormalities (maternal acidosis, hyperglycaemia, electrolyte imbalance), resulting in fetal hypoxaemia and acidosis. In fetuses with mature cardiac activity, the fetal heart rate may show minimal or absent variability, repetitive deceleration and absence of acceleration. These abnormalities in heart rate usually resolve with resolution of the DKA, which may last for several hours before normalisation.For the patient reported on here, immediate delivery based on pathological fetal heart rate would have resulted in preterm delivery and jeopardised the maternal clinical condition. However, a holistic clinical approach by the multidisciplinary team to management of the patient led to normal term delivery 5 weeks after presentation with DKA; fetal and maternal outcome were good.


Asunto(s)
Diabetes Mellitus , Cetoacidosis Diabética , Embarazo en Diabéticas , Recién Nacido , Embarazo , Humanos , Femenino , Cetoacidosis Diabética/complicaciones , Cetoacidosis Diabética/diagnóstico , Cetoacidosis Diabética/terapia , Feto , Polidipsia , Tercer Trimestre del Embarazo
2.
Indian J Pediatr ; 89(12): 1251-1256, 2022 12.
Artículo en Inglés | MEDLINE | ID: mdl-35653075

RESUMEN

OBJECTIVE: To develop and validate a mobile application-based tool for the management guidance of children and adolescents with diabetic ketoacidosis (DKA). METHODS: The study involved the development of a mobile application-based tool for DKA management in accordance with the International Society of Pediatric and Adolescent Diabetes (ISAPD) guidelines, 2018. The impact of the mobile application in preventing protocol deviation and resultant complications was assessed. Case records of 70 children and adolescents [39 boys, 8.9 (4.1) y of age] with severe DKA managed in the authors' intensive care unit were examined. The application guidance and real-time management were compared to the standard protocol. RESULTS: Protocol deviations were observed in 58 (82.9%), with two or more errors in 28 (40%). These included lack of initial fluid bolus (4, 5.7%), excessive fluid supplementation (8, 11.4%), inadequate initial fluid (25, 35.7%) and potassium supplementation (13, 18.6%), delayed response to fall in potassium (15, 21.4%) and glucose levels (24, 34.3%), and erroneous insulin administration (19, 27.1%). These errors contributed to 42.1% of severe hypokalemia and 56% of significant hypoglycemia episodes. The mobile application guidance was in accordance with the protocol in all the case scenario. CONCLUSION: Deviation from the management protocol is common in DKA and associated with adverse outcomes. Mobile application guidance is expected to reduce the protocol deviation with a potential of improving outcomes.


Asunto(s)
Diabetes Mellitus , Cetoacidosis Diabética , Aplicaciones Móviles , Masculino , Adolescente , Niño , Humanos , Cetoacidosis Diabética/terapia , Cetoacidosis Diabética/complicaciones , Estudios Retrospectivos , Insulina/uso terapéutico , Potasio , Diabetes Mellitus/inducido químicamente
3.
Can J Diabetes ; 46(3): 269-276.e2, 2022 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-35568428

RESUMEN

BACKGROUND: Diabetic ketoacidosis (DKA) is a common acute life-threatening complication of poorly controlled diabetes mellitus contributing to considerable mortality and morbidity. Use of standardized treatment protocols improves patient outcomes in the emergency department (ED) for many conditions, but variability in adult DKA treatment protocols has not been assessed across EDs. In this study, we compared DKA treatment protocols from adult EDs across Canada to highlight inconsistencies in recommended DKA management. METHODS: ED staff in Canada were solicited for their treatment protocols used to guide acute ED DKA management. Information regarding initial fluid resuscitation and maintenance fluid, potassium replacement, insulin therapy and bicarbonate administration was abstracted from each protocol, collated in a table and compared. RESULTS: Thirty-six unique protocols were obtained representing 85 institutions (40 urban and 45 rural, with a 65.1% response rate) across Canada, with no protocol use for 4 urban centres. Similarities in protocols included the intravenous insulin infusion rate and instructions for switching to subcutaneous insulin. Variability was noted in the rate, amount and type of fluid bolus given (0.5 to 2 L of normal saline or Ringer's lactate over 15 minutes to 2 hours), the criteria determining the amount, potassium supplementation at normo/hypokalemic ranges, when to add dextrose to maintenance fluid, insulin bolus inclusion and bicarbonate administration. CONCLUSIONS: This is the first comparison of adult DKA treatment protocols in Canada. Although several common approaches were identified, variability was found in initial fluid boluses, initial insulin bolus and role of bicarbonate, necessitating further study to ensure local DKA protocols reflect current evidence-based best practices for optimal patient clinical outcomes.


Asunto(s)
Diabetes Mellitus , Cetoacidosis Diabética , Adulto , Bicarbonatos/uso terapéutico , Canadá/epidemiología , Protocolos Clínicos , Diabetes Mellitus/tratamiento farmacológico , Cetoacidosis Diabética/tratamiento farmacológico , Cetoacidosis Diabética/terapia , Servicio de Urgencia en Hospital , Humanos , Insulina/uso terapéutico , Potasio/uso terapéutico
4.
Cardiol Young ; 32(10): 1677-1680, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-35094738

RESUMEN

Diabetic ketoacidosis is one of the most serious and common complications of diabetes, with between 15 and 70% of new-onset type 1 diabetes mellitus worldwide presented with diabetic ketoacidosis. Supraventricular tachycardia, however, is an infrequent complication of diabetic ketoacidosis. We present the case of a child with a new-onset type 1 diabetes mellitus with supraventricular tachycardia as a complication of paediatric diabetic ketoacidosis. The patient received intravenous fluid resuscitation, insulin, and potassium supplementation and subsequently developed stable supraventricular tachycardia initially, confirmed on a 12-lead electrocardiogram despite a structurally normal heart and normal electrolytes. Vagal manoeuvers failed to achieve sinus rhythm. The patient went into respiratory distress and was intubated, for mechanical ventilation. She received one dose of adenosine with successful conversion to sinus rhythm and a heart rate decreased from 200 to 140 beats per minutes. We conclude that supraventricular tachycardia can occur as a complication of diabetic ketoacidosis, including in new-onset type 1 diabetes mellitus. Furthermore, a combination of acidosis, potassium derangement, falling magnesium, and phosphate levels may have precipitated the event. Here, we report a case of supraventricular tachycardia as a complication of paediatric diabetic ketoacidosis.


Asunto(s)
Diabetes Mellitus Tipo 1 , Cetoacidosis Diabética , Taquicardia Supraventricular , Humanos , Niño , Femenino , Cetoacidosis Diabética/complicaciones , Cetoacidosis Diabética/diagnóstico , Cetoacidosis Diabética/terapia , Diabetes Mellitus Tipo 1/complicaciones , Magnesio/uso terapéutico , Taquicardia Supraventricular/diagnóstico , Taquicardia Supraventricular/etiología , Insulina/uso terapéutico , Adenosina , Potasio/uso terapéutico , Electrólitos/uso terapéutico , Fosfatos
5.
Medicine (Baltimore) ; 100(51): e27920, 2021 Dec 23.
Artículo en Inglés | MEDLINE | ID: mdl-34941035

RESUMEN

ABSTRACT: To explore the effects of nutritional support combined with insulin therapy on serum protein, procalcitonin (PCT), C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), pentraxin-3 (PTX-3), and serum amylase (AMS) levels in patients with diabetic ketoacidosis complicated with acute pancreatitis.A total of 64 patients with diabetic ketoacidosis complicated with acute pancreatitis admitted to our hospital from January 2018 to February 2019 were enrolled in this prospective study. They were divided into the study group and the control group according to the random number table method, with 32 patients in each group. Patients in the study group were given nutritional support combined with insulin therapy, and patients in the control group were given insulin therapy.There were no significant differences in general data including age, gender, body mass index, course and type of diabetes, acute physiology and chronic health evaluation II, RANSON, CT grades between the 2 groups before treatment (all P > .05). After 7 days of treatment, the clinical efficacy of the study group was significantly higher than that of the control group (study group vs control group, 94.44% vs 75.00%, P < .05). After 7 days of treatment, the levels of prealbumin and albumin in the study group were significantly higher than those in the control group (P < .05). After 7 days of treatment, the levels of PCT, CRP, TNF-α, PTX-3, and AMS in the 2 groups were significantly lower than those before treatment (P < .05), and the levels of PCT, CRP, TNF-α, PTX-3, and AMS in the study group were significantly lower than those in the control group. After 7 days of treatment, the levels of IgG, IgM, and IgA in the 2 groups were significantly higher than those before treatment, and the levels of IgG, IgM, and IgA in the study group were significantly higher than those in the control group (P < .05).Nutritional support combined with insulin is obviously effective in the treatment of diabetic ketoacidosis complicated with acute pancreatitis, which can improve serum protein levels, reduce inflammatory response, improve immune function, and is worthy of clinical application.


Asunto(s)
Cetoacidosis Diabética/sangre , Cetoacidosis Diabética/terapia , Insulina/uso terapéutico , Apoyo Nutricional , Pancreatitis/terapia , Enfermedad Aguda , Adulto , Anciano , Amilasas/sangre , Proteína C-Reactiva/análisis , Cetoacidosis Diabética/diagnóstico , Humanos , Inmunoglobulina A/sangre , Inmunoglobulina G/sangre , Inmunoglobulina M/sangre , Persona de Mediana Edad , Pancreatitis/complicaciones , Polipéptido alfa Relacionado con Calcitonina/sangre , Polipéptido alfa Relacionado con Calcitonina/efectos de los fármacos , Estudios Prospectivos , Componente Amiloide P Sérico , Factor de Necrosis Tumoral alfa/sangre
6.
Ital J Pediatr ; 45(1): 42, 2019 Apr 02.
Artículo en Inglés | MEDLINE | ID: mdl-30940174

RESUMEN

BACKGROUND: Hypophosphatemia has many causes, and is often encountered during DKA (Diabetic Ketoacidosis) treatment. However, it rarely requires clinical intervention. CASE PRESENTATION: Ventricular arrhythmia was observed in a 10-year-old girl with newly diagnosed type 1 diabetes mellitus and hypophosphatemia while undergoing treatment for ketoacidosis. Oral phosphate supplementation ceased ventricular arrhythmia almost completely. CONCLUSIONS: The clinical signs of hypophosphatemia are potentially life-threatening. Therefore, physicians should be vigilant when treating patients who are at risk of hypophosphatemia. Severe hypophosphatemia accompanied by clinical symptoms requires oral or intravenous supplementation of phosphate.


Asunto(s)
Cetoacidosis Diabética/terapia , Hipofosfatemia/complicaciones , Hipofosfatemia/etiología , Taquicardia Ventricular/etiología , Niño , Diabetes Mellitus Tipo 1 , Femenino , Fluidoterapia/efectos adversos , Humanos , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/efectos adversos , Infusiones Intravenosas , Insulina/administración & dosificación , Insulina/efectos adversos , Fosfatos/administración & dosificación , Taquicardia Ventricular/terapia
7.
Pediatr Diabetes ; 19(5): 985-992, 2018 08.
Artículo en Inglés | MEDLINE | ID: mdl-29573523

RESUMEN

OBJECTIVE: This study examines temporal trends in treatment-related outcomes surrounding a diabetic ketoacidosis (DKA) performance improvement intervention consisting of mandated intensive care unit admission and implementation of a standardized management pathway, and identifies physical and biochemical characteristics associated with outcomes in this population. METHODS: A retrospective cohort of 1225 children with DKA were identified in the electronic health record by international classification of diseases codes and a minimum pH less than 7.3 during hospitalization at a quaternary children's hospital between April, 2009 and May, 2016. Multivariable regression examined predictors and trends of hypoglycemia, central venous line placement, severe hyperchloremia, head computed tomography (CT) utilization, treated cerebral edema and hospital length of stay (LOS). RESULTS: The incidence of severe hyperchloremia and head CT utilization decreased during the study period. Among patients with severe DKA (presenting pH < 7.1), the intervention was associated with decreasing LOS and less variability in LOS. Lower pH at presentation was independently associated with increased risk for all outcomes except hypoglycemia, which was associated with higher pH. Patients treated for cerebral edema had a lower presenting mean systolic blood pressure z score (0.58 [95% confidence interval (CI) -0.02-1.17] vs 1.23 [1.13-1.33]) and a higher maximum mean systolic blood pressure (SBP) z score during hospitalization (3.75 [3.19-4.31] vs 2.48 [2.38-2.58]) compared to patients not receiving cerebral edema treatment. Blood pressure and cerebral edema remained significantly associated after covariate adjustment. CONCLUSION: Treatment-related outcomes improved over the entire study period and following a performance improvement intervention. The association of SBP with cerebral edema warrants further study.


Asunto(s)
Cetoacidosis Diabética/terapia , Adolescente , Presión Sanguínea , Edema Encefálico/etiología , Niño , Vías Clínicas , Cetoacidosis Diabética/complicaciones , Femenino , Humanos , Masculino , Estudios Retrospectivos , Resultado del Tratamiento
8.
J Diabetes Complications ; 31(2): 468-472, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-27499457

RESUMEN

AIMS: Patients with type 1 diabetes often develop diabetic ketoacidosis (DKA). Reportedly, DKA in type 2 diabetes has higher mortality despite its limited occurrence. The exact clinical characteristics and therapeutic modalities yielding successful outcomes in DKA type 2 diabetes remain unknown. METHODS: This retrospective study compared the clinical features and detailed treatment of consecutive type 1 and type 2 diabetes patients hospitalized with DKA between January 2001 and December 2014. RESULTS: We report on 127 patients with type 1 and 74 patients with type 2 diabetes whose DKA was successfully treated. The most frequent precipitating cause for DKA was infectious disease for patients with type 1 diabetes and consumption of sugar-containing beverages for those with type 2 diabetes. Type 2 diabetes patients showed higher mean plasma glucose levels than those with type 1 diabetes (48.4±21.6, vs. 37.1±16.4mmol/l, P<0.01) and higher serum creatinine, blood urea nitrogen, and hemoglobin levels, which normalized after DKA resolution. Compared with type 1 diabetes patients, those with type 2 diabetes required distinctly higher daily total insulin dosage (35.9±37.0U, vs. 20.2±23.3U, P<0.01), larger replacement fluid volumes (4.17±2.69L, vs. 2.29±1.57L, P<0.01) and greater potassium supplementation (23.9±36.5mEq, vs. 11.2±17.9mEq, P<0.01) to resolve DKA and reduce plasma glucose level to ≤16.7mmol/l. CONCLUSIONS: DKA patients with type 2 diabetes required management with a modified treatment protocol to resolve their profound hyperglycemia and dehydration compared with those with type 1 diabetes.


Asunto(s)
Diabetes Mellitus Tipo 1/terapia , Diabetes Mellitus Tipo 2/terapia , Cetoacidosis Diabética/prevención & control , Adulto , Anciano , Bebidas/efectos adversos , Glucemia/análisis , Terapia Combinada/efectos adversos , Enfermedades Transmisibles/complicaciones , Enfermedades Transmisibles/fisiopatología , Deshidratación/etiología , Deshidratación/fisiopatología , Deshidratación/prevención & control , Deshidratación/terapia , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/etnología , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/etnología , Cetoacidosis Diabética/etiología , Cetoacidosis Diabética/fisiopatología , Cetoacidosis Diabética/terapia , Azúcares de la Dieta/efectos adversos , Progresión de la Enfermedad , Femenino , Hospitales Universitarios , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Centros de Atención Terciaria
9.
Vet Clin North Am Small Anim Pract ; 47(2): 491-503, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-28017407

RESUMEN

Diabetic ketoacidosis is a dynamic disease that requires regular reassessment of an affected patient. Typical treatment regimens include crystalloid fluid therapy, insulin, and supplementation of dextrose, phosphorus, and potassium. This article presents an approach to and considerations for treatment of a diabetic ketoacidotic dog or cat.


Asunto(s)
Enfermedades de los Gatos/terapia , Cetoacidosis Diabética/veterinaria , Enfermedades de los Perros/terapia , Fluidoterapia/veterinaria , Desequilibrio Hidroelectrolítico/veterinaria , Animales , Enfermedades de los Gatos/fisiopatología , Gatos , Cetoacidosis Diabética/fisiopatología , Cetoacidosis Diabética/terapia , Enfermedades de los Perros/fisiopatología , Perros , Electrólitos , Fluidoterapia/métodos , Hipoglucemiantes/uso terapéutico , Insulina/uso terapéutico , Desequilibrio Hidroelectrolítico/terapia
10.
Nutr Metab Cardiovasc Dis ; 26(12): 1104-1111, 2016 12.
Artículo en Inglés | MEDLINE | ID: mdl-27817991

RESUMEN

BACKGROUND AND AIMS: To assess temporal trend in incidence (2003-12) and prevalence (2002-12) of type 1 diabetes in children and young adults, direct costs and selected indicators of quality of care under the coverage of the universalistic Italian National Health System (NHS). METHODS AND RESULTS: The ARNO Observatory, a healthcare monitoring system based on administrative data, identified a population-based multiregional cohort of subjects aged 0-29 years. Type 1 diabetes was defined by at least two prescriptions of insulin over 12 months and continuous insulin-treatment in the following year. Indicators of quality of care and directs costs were assessed in persons with diabetes and in people without diabetes, individually matched for age, gender and health unit (1:4 ratio). We identified 2357 incident cases of type 1 diabetes aged 0-29 years (completeness of ascertainment, 99%). Incidence rates were similar in ages 0-14 (15.8, 95% CI 14.9-16.8) and 15-29 years (16.3, 15.4-17.2), with no significant trend. Prevalence increased from 137 to 166.9/100,000, particularly in the age 15-29 years. Direct costs accounted for € 2117 in persons with diabetes and € 292 in control individuals. A statistically significant decreasing trend in hospitalization for acute complications was evident (p < 0.001), which was almost completely due to ketoacidosis. People with at least one HbA1c measurement over the year were 48.5%. CONCLUSION: We showed high incidence and increasing prevalence of type 1 diabetes in young adults in Italy, which impact on direct costs under the universalistic coverage of the NHS.


Asunto(s)
Diabetes Mellitus Tipo 1/tratamiento farmacológico , Diabetes Mellitus Tipo 1/economía , Costos de los Medicamentos , Hipoglucemiantes/economía , Hipoglucemiantes/uso terapéutico , Insulina/economía , Insulina/uso terapéutico , Indicadores de Calidad de la Atención de Salud/economía , Adolescente , Adulto , Biomarcadores/sangre , Glucemia/efectos de los fármacos , Glucemia/metabolismo , Niño , Preescolar , Análisis Costo-Beneficio , Diabetes Mellitus Tipo 1/diagnóstico , Diabetes Mellitus Tipo 1/epidemiología , Cetoacidosis Diabética/economía , Cetoacidosis Diabética/epidemiología , Cetoacidosis Diabética/terapia , Femenino , Hemoglobina Glucada/metabolismo , Costos de Hospital , Humanos , Hipoglucemiantes/efectos adversos , Incidencia , Lactante , Recién Nacido , Insulina/efectos adversos , Italia/epidemiología , Masculino , Programas Nacionales de Salud/economía , Prevalencia , Factores de Tiempo , Resultado del Tratamiento , Adulto Joven
11.
Clin Calcium ; 26(3): 459-62, 2016 Mar.
Artículo en Japonés | MEDLINE | ID: mdl-26923986

RESUMEN

In this session, we describe the acute phase in patients with metabolic syndrome from two sides; acute disease that occurs higher in patients with metabolic syndrome such as colonary heart disease and stroke, and acute aggravation of diabetes such as diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome. The electrolyte imbalance is frequently detected in critical ill patients. It is reported that the extreme abnormalities of ionized calcium concentrations are independent predictors of mortality. In addition, from clinical database MIMIC-Ⅱ,calcium supplementation improves clinical outcome in intensive care unit patients. Although metabolic syndrome; lifestyle-related disease, is a chronic disease, the possibility of falling into acute disease by having it becomes very high and improvement of electrolyte imbalance, especially hypocalcaemia is expected to effective on clinical outcome.


Asunto(s)
Calcio/metabolismo , Cetoacidosis Diabética/metabolismo , Hiperglucemia/metabolismo , Síndrome Metabólico/metabolismo , Estado Nutricional/fisiología , Accidente Cerebrovascular/terapia , Cetoacidosis Diabética/terapia , Humanos , Síndrome Metabólico/terapia
12.
JNMA J Nepal Med Assoc ; 53(198): 137-40, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26994037

RESUMEN

Rhabdomyolysis is a syndrome characterized by injury to skeletal muscle fibers with disruption and release of toxic metabolites into circulation. It is characterized by triad of muscle weakness, myalgia and dark urine and is associated with increased creatine kinase and lactate dehydrogenase. A severely malnourished 10 year old girl with severe diabetic ketoacidosis as hemr initial presentation of type 1 diabetes mellitus developed rhabdomyolysis (CK- 12,000 U/L) with non-oliguric renal failure during her initial course of hospital stay. The possible cause of her RM was attributed to severe hypophosphatemia (minimum serum phosphate, 0.8 mg/dL). Management of diabetic ketoacidosis phosphate supplementation and urinary alkalinization with diuresis improved her clinical course. She was discharged on Day 9 with Insulin. We recommend frequent monitoring of serum phosphate during early period of DKA, particularly in malnourished children, and its normalization in case of severe hypophosphatemia.


Asunto(s)
Diabetes Mellitus Tipo 1/complicaciones , Cetoacidosis Diabética/complicaciones , Hipofosfatemia/complicaciones , Rabdomiólisis/etiología , Niño , Diabetes Mellitus Tipo 1/diagnóstico , Cetoacidosis Diabética/metabolismo , Cetoacidosis Diabética/terapia , Femenino , Fluidoterapia , Humanos , Hipoglucemiantes/uso terapéutico , Hipofosfatemia/terapia , Insulina/uso terapéutico , Fosfatos/uso terapéutico , Rabdomiólisis/terapia , Índice de Severidad de la Enfermedad , Bicarbonato de Sodio/uso terapéutico
13.
Lima; s.n; 2013. 77 p. tab, graf.
Tesis en Español | LILACS, LIPECS | ID: biblio-1113184

RESUMEN

Objetivos: Conocer las características clínicas, epidemiológicas (sexo, edad, antecedentes, factores desencadenantes) y las diferencias del tratamiento con insulina endovenosa vs intramuscular en los pacientes con diagnóstico de CAD (cetoacidosis) que ingresaron en el servicio de emergencia del Hospital Nacional Daniel Alcides Carrión durante el periodo Agosto 2005-Mayo 2012. Material y métodos: Se realizó un estudio observacional, analítico, retrospectivo y transversal. Se revisaron 51 historias clínicas de pacientes con diagnóstico de CAD que ingresaron en el periodo de tiempo del estudio. Resultados: la media de la edad de los pacientes fue 46.01+/-14.5 años. El 58.8 por ciento de los pacientes fueron del sexo femenino. El 35.3 por ciento debutaban con un episodio de cetoacidosis diabética. La medicación más frecuente que recibían los pacientes eran los hipoglicemiantes orales en un 35.3 por ciento de los casos. El 47.1 por ciento de los pacientes eran obesos. EL 47.1 por ciento de los pacientes tenían el antecedente de diabetes. El 35.3 por ciento de los pacientes tuvieron poliuria como síntoma más frecuente. El 23.5 por ciento de los pacientes presentaron somnolencia. El 62.7 por ciento de los pacientes abandonaron el tratamiento. El 58.8 por ciento de los pacientes recibieron insulina por infusión continua y el 41.2 por ciento recibieron insulina por dosis horaria intramuscular. La complicación más frecuente fue la hipoglicemia que se presentó en el 45.1 por ciento de los casos. Conclusiones: La infusión continua fue más usada en los pacientes del sexo femenino (73.3 por ciento), y las dosis horarias fueron usadas con mayor frecuencia en el sexo masculino (61.9 por ciento) (P<0.05). La insulina horaria fue más usada en pacientes obesos (76.2 por ciento) (P<0.05). Hubo una diferencia estadísticamente significativa entorno al PH, potasio final y menor tiempo de hospitalización con la insulina por infusión continua, y menor dosis de insulina con las...


Asunto(s)
Masculino , Femenino , Humanos , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Cetoacidosis Diabética/epidemiología , Cetoacidosis Diabética/terapia , /terapia , Insulina/uso terapéutico , Posología Homeopática , Estudio Observacional , Estudios Longitudinales , Estudios Retrospectivos , Estudios Transversales
14.
Crit Care Clin ; 28(4): 601-31, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22998993

RESUMEN

Ketoacidotic syndromes are frequently encountered in acute care medicine. This article focuses on ketosis and ketoacidotic syndromes associated with intoxications, alcohol abuse, starvation, and certain dietary supplements as well as inborn errors of metabolism. Although all of these various processes are characterized by the accumulation of ketone bodies and metabolic acidosis, there are differences in the mechanisms, clinical presentations, and principles of therapy for these heterogeneous disorders. Pathophysiologic mechanisms that account for these disorders are presented, as well as guidance regarding identification and management.


Asunto(s)
Equilibrio Ácido-Base , Cetonas/metabolismo , Cetosis/etiología , Cetosis/terapia , Alcoholismo/complicaciones , Cuidados Críticos , Cetoacidosis Diabética/diagnóstico , Cetoacidosis Diabética/etiología , Cetoacidosis Diabética/metabolismo , Cetoacidosis Diabética/terapia , Dieta Cetogénica/efectos adversos , Sobredosis de Droga/complicaciones , Sobredosis de Droga/diagnóstico , Sobredosis de Droga/terapia , Humanos , Cetosis/diagnóstico , Cetosis/metabolismo , Errores Innatos del Metabolismo/complicaciones , Trastornos Nutricionales/complicaciones , Intoxicación/complicaciones
16.
Av. diabetol ; 24(3): 237-243, mayo-jun. 2008. ilus, tab
Artículo en Es | IBECS | ID: ibc-68037

RESUMEN

El objetivo de este trabajo era evaluar la eficacia del tratamiento con múltiples dosis de insulina (MDI) utilizando insulina glargina como insulina basal y lispro como insulina prandial. Cuarenta y cinco pacientes con diabetes tipo 1 (DM1) y un control metabólico inadecuado con terapia intensiva con insulina protamina neutra de Hagedorn (NPH) e insulina rápida, fueron tratados con una dosis de insulina glargina asociada a 3 o más dosis de insulina lispro preprandial durante 5 meses. Antes y después del tratamiento, se analizaron variables clínicas, analíticas y grado de satisfacción con el tratamiento, y se efectuó una monitorización continua de glucosa durante 48 horas al final del estudio. Los resultados fueron los siguientes: con la terapia basal-bolos se observó un aumento del índice de masa corporal (24,0 ± 3,5 frente a 24,4 ± 3,4 kg/m2; p <0,05), una reducción de las necesidades de insulina (0,86 ± 0,28 frente a 0,72 ± 0,20 UI/kg/día; p <0,001) y una disminución de los episodios de hipoglucemia grave. Al mismo tiempo, un descenso significativo tanto de la glucemia basal (189 ± 78 frente a 145 ± 58 mg/dL; p= 0,005) como de los niveles de hemoglobina glucosilada (HbA1c) (8,5 ± 1,1 frente a 7,8 ± 0,8%; p= 0,001), así como una evidente mejora en el grado de satisfacción con el tratamiento. En conclusión, el tratamiento con MDI en régimen bolos-basal con insulina glargina como insulina basal reduce la glucemia basal y el nivel de HbA1c, con menores requerimientos de insulina, e induce un ligero incremento ponderal. Además, esta terapia consigue una reducción significativa de los episodios de hipoglucemia grave, con una mejora importante en el grado de satisfacción del paciente con el tratamiento (AU)


Our aim was to evaluate the efficacy of treatment with multiple daily injections (MDI) using insulin glargine as basal insulin and insulin lispro as prandial insulin. Forty-five patients with type 1 diabetes and inadequate metabolic control with intensive therapy based on NPH insulin and rapid-acting insulin were treated with insulin glargine once daily associated with 3 or more doses of preprandial lispro insulin during 5 months. Clinical and analytical variables and satisfaction with treatment were analyzed before and after treatment, and a continuous glucose monitoring was performed during 48 hours at the end of the study. An increase in body mass index (24.01 ± 3.55 versus 24.42 ± 3.38 kg/m2, p <0.05), a reduction in insulin requirements (0.86 ± 0.28 versus 0.72 ± 0.20 IU/kg/day, p <0.001) and diminution of severe hypoglycemia episodes were observed with the basal-bolus therapy. At the same time, a significant decrease of fasting plasma glucose levels (189 ± 78 versus 145 ± 58 mg/dl, p= 0.005) and HbA1c levels (8.5 ± 1.1 versus 7.8 ± 0.8%, p= 0001), as well as an improvement in the degree of satisfaction with treatment were observed. In conclusion, treatment with MDI in basalbolus regimen with insulin glargine as basal insulin reduces fasting plasma glucose and HbA1c levels, with lower insulin requirements and a slight weight increase. Furthermore, this therapy achieves a significant reduction of episodes of severe hypoglycemia with an important improvement in the degree of treatment patient satisfaction (AU)


Asunto(s)
Humanos , Masculino , Femenino , Niño , Adolescente , Adulto , Persona de Mediana Edad , Insulina/uso terapéutico , Diabetes Mellitus Tipo 1/terapia , Posología Homeopática/estadística & datos numéricos , Metabolismo Basal/fisiología , Hipoglucemia/complicaciones , Hipoglucemia/diagnóstico , Encuestas y Cuestionarios , Modelos Lineales , Análisis Multivariante , Satisfacción del Paciente/estadística & datos numéricos , Índice de Masa Corporal , Cetoacidosis Diabética/diagnóstico , Cetoacidosis Diabética/terapia
17.
Diabet Med ; 24(4): 359-63, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17298587

RESUMEN

AIMS: Integrated Care Pathways (ICPs) are management plans that indicate the sequence and timing of the optimal treatment for individuals with a given disorder. The treatment of diabetic ketoacidosis (DKA) before and after the implementation of an ICP in a teaching hospital was examined. METHODS: Twenty-seven episodes of DKA were identified during the 13-month control period and 22 in the 13 months following implementation of the ICP. Case notes were reviewed and relevant clinical data extracted. RESULTS: The introduction of the ICP was associated with a reduction in the time taken to initiate intravenous fluid [45.0 (5-225) min to 37.5 (0-135) min; P = 0.01]. Time taken to initiate insulin infusion was also reduced [60.0 (5-755) min to 37.5 (0-175) min; P = 0.02]. The proportion of patients commenced on intravenous insulin within 60 min increased from 48 to 77% (P = 0.04). In addition, there was a reduction in the prescription of antibiotics (48-18%; P = 0.028) and low molecular weight heparin (59-5%; P < 0.001). Length of stay was not affected. CONCLUSION: The ICP significantly improved key areas in the management of DKA, although there remains room for further improvements.


Asunto(s)
Vías Clínicas/organización & administración , Diabetes Mellitus Tipo 1/terapia , Cetoacidosis Diabética/terapia , Hipoglucemiantes/uso terapéutico , Insulina/uso terapéutico , Adolescente , Adulto , Femenino , Hospitalización , Hospitales de Enseñanza , Humanos , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Evaluación de Procesos y Resultados en Atención de Salud , Factores de Tiempo , Resultado del Tratamiento
18.
Diabetes Res Clin Pract ; 77(1): 113-9, 2007 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-17126447

RESUMEN

The aims of this study were to investigate management routines of diabetic ketoacidosis (DKA) in adult patients in departments of internal medicine in Denmark and to relate current routines of treatment to available evidence. A questionnaire requesting information on management routines of DKA was sent to all departments of internal medicine in Denmark responsible of managing DKA. Fifty-nine departments (88%) returned the questionnaire and/or a copy of their management protocol. At 19 departments (32%), all patients with DKA were managed in an intensive care unit (ICU). Twenty-four different insulin regimens and 21 fluid protocols were identified. Routines of insulin therapy varied in terms of doses and routes of administration. Fifty-eight departments (97%) used isotonic saline for hydration. Potassium supplements were administered as a separate infusion of either isotonic potassium-sodium-chloride (83%) or isotonic potassium-chloride (10%). Recommended volumes to be administered during the first 8h of treatment varied significantly (median 4800ml, range 3750-7700ml). Use of bicarbonate was endorsed by 80%. This study shows significant variations in management routines of DKA in Denmark. In many cases, the treatment routines employed are not supported by evidence from clinical trials. We recommend implementation of national and/or European guidelines for management of DKA in adult patients.


Asunto(s)
Cetoacidosis Diabética/terapia , Encuestas de Atención de la Salud , Medicina Interna/métodos , Manejo de Atención al Paciente/métodos , Pautas de la Práctica en Medicina/estadística & datos numéricos , Adulto , Bicarbonatos/uso terapéutico , Dinamarca , Fluidoterapia/estadística & datos numéricos , Humanos , Insulina/administración & dosificación , Unidades de Cuidados Intensivos , Medicina Interna/normas , Soluciones Isotónicas/uso terapéutico , Manejo de Atención al Paciente/normas , Guías de Práctica Clínica como Asunto/normas , Cloruro de Sodio/uso terapéutico , Encuestas y Cuestionarios
19.
Clin Infect Dis ; 43(1): e6-8, 2006 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-16758409

RESUMEN

Acupuncture use is increasing in the United States. Despite multiple studies, the efficacy and safety of acupuncture are poorly defined. We report a previously healthy patient who developed a thigh abscess, bacteremia, and diabetic ketoacidosis after acupuncture treatment. We review the literature on infectious complications of acupuncture.


Asunto(s)
Absceso/etiología , Terapia por Acupuntura/efectos adversos , Cetoacidosis Diabética/etiología , Infecciones Estafilocócicas/etiología , Staphylococcus aureus , Absceso/terapia , Adulto , Antibacterianos/uso terapéutico , Bacteriemia/etiología , Bacteriemia/terapia , Cetoacidosis Diabética/terapia , Drenaje/métodos , Humanos , Masculino , Infecciones Estafilocócicas/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA